Research programme: West Nile virus monoclonal antibodies - CrucellAlternative Names: WNV monoclonal antibodies
Latest Information Update: 20 Jun 2011
At a glance
- Originator Crucell
- Class Monoclonal antibodies
- Mechanism of Action Virus attachment inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued West Nile virus infections
Most Recent Events
- 14 Aug 2007 Commercial options are being explored for this programme